EDSA
Price
$2.05
Change
+$0.10 (+5.13%)
Updated
Jun 27 closing price
Capitalization
14.4M
ORMP
Price
$2.15
Change
-$0.02 (-0.92%)
Updated
Jun 27 closing price
Capitalization
87.83M
45 days until earnings call
Interact to see
Advertisement

EDSA vs ORMP

Header iconEDSA vs ORMP Comparison
Open Charts EDSA vs ORMPBanner chart's image
Edesa Biotech
Price$2.05
Change+$0.10 (+5.13%)
Volume$2.88K
Capitalization14.4M
Oramed Pharmaceuticals
Price$2.15
Change-$0.02 (-0.92%)
Volume$59.11K
Capitalization87.83M
EDSA vs ORMP Comparison Chart in %
Loading...
EDSA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ORMP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EDSA vs. ORMP commentary
Jun 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EDSA is a StrongBuy and ORMP is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 29, 2025
Stock price -- (EDSA: $2.05 vs. ORMP: $2.15)
Brand notoriety: EDSA and ORMP are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EDSA: 13% vs. ORMP: 86%
Market capitalization -- EDSA: $14.4M vs. ORMP: $87.83M
EDSA [@Biotechnology] is valued at $14.4M. ORMP’s [@Biotechnology] market capitalization is $87.83M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EDSA’s FA Score shows that 0 FA rating(s) are green whileORMP’s FA Score has 0 green FA rating(s).

  • EDSA’s FA Score: 0 green, 5 red.
  • ORMP’s FA Score: 0 green, 5 red.
According to our system of comparison, ORMP is a better buy in the long-term than EDSA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EDSA’s TA Score shows that 4 TA indicator(s) are bullish while ORMP’s TA Score has 1 bullish TA indicator(s).

  • EDSA’s TA Score: 4 bullish, 3 bearish.
  • ORMP’s TA Score: 1 bullish, 8 bearish.
According to our system of comparison, EDSA is a better buy in the short-term than ORMP.

Price Growth

EDSA (@Biotechnology) experienced а +4.59% price change this week, while ORMP (@Biotechnology) price change was +0.94% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.22%. For the same industry, the average monthly price growth was +31.37%, and the average quarterly price growth was +12.88%.

Reported Earning Dates

EDSA is expected to report earnings on May 14, 2025.

ORMP is expected to report earnings on Aug 13, 2025.

Industries' Descriptions

@Biotechnology (+4.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ORMP($87.8M) has a higher market cap than EDSA($14.4M). EDSA YTD gains are higher at: 22.024 vs. ORMP (-11.157). EDSA has higher annual earnings (EBITDA): -5.68M vs. ORMP (-21.53M). ORMP has more cash in the bank: 131M vs. EDSA (13.9M). EDSA has less debt than ORMP: EDSA (0) vs ORMP (301K). ORMP has higher revenues than EDSA: ORMP (2M) vs EDSA (0).
EDSAORMPEDSA / ORMP
Capitalization14.4M87.8M16%
EBITDA-5.68M-21.53M26%
Gain YTD22.024-11.157-197%
P/E RatioN/A20.91-
Revenue02M-
Total Cash13.9M131M11%
Total Debt0301K-
FUNDAMENTALS RATINGS
EDSA vs ORMP: Fundamental Ratings
EDSA
ORMP
OUTLOOK RATING
1..100
216
VALUATION
overvalued / fair valued / undervalued
1..100
98
Overvalued
59
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9893
PRICE GROWTH RATING
1..100
6376
P/E GROWTH RATING
1..100
10051
SEASONALITY SCORE
1..100
5075

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ORMP's Valuation (59) in the Pharmaceuticals Other industry is somewhat better than the same rating for EDSA (98) in the null industry. This means that ORMP’s stock grew somewhat faster than EDSA’s over the last 12 months.

ORMP's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as EDSA (100) in the null industry. This means that ORMP’s stock grew similarly to EDSA’s over the last 12 months.

ORMP's SMR Rating (93) in the Pharmaceuticals Other industry is in the same range as EDSA (98) in the null industry. This means that ORMP’s stock grew similarly to EDSA’s over the last 12 months.

EDSA's Price Growth Rating (63) in the null industry is in the same range as ORMP (76) in the Pharmaceuticals Other industry. This means that EDSA’s stock grew similarly to ORMP’s over the last 12 months.

ORMP's P/E Growth Rating (51) in the Pharmaceuticals Other industry is somewhat better than the same rating for EDSA (100) in the null industry. This means that ORMP’s stock grew somewhat faster than EDSA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EDSAORMP
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
89%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
72%
Momentum
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
84%
MACD
ODDS (%)
Bullish Trend 2 days ago
72%
Bearish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
83%
Advances
ODDS (%)
N/A
Bullish Trend 4 days ago
82%
Declines
ODDS (%)
Bearish Trend 18 days ago
87%
Bearish Trend 2 days ago
83%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
85%
Aroon
ODDS (%)
Bearish Trend 2 days ago
87%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
EDSA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ORMP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TLPFY47.780.87
+1.85%
Teleperformance
BSEM13.500.12
+0.93%
BioStem Technologies, Inc.
RLXXF53.50N/A
N/A
RELX PLC
CLPHY8.41-0.05
-0.53%
CLP Holdings Ltd.
CYFRF1.63-0.07
-4.12%
SOL STRATEGIES INC.